Analysis of a New Biomarker for Prostate Cancer Diagnosis

• Conditions: Patients With Suspected Prostate Cancer
• Interventions: Other: determine the levels of the "HEM" substance in seminal plasma

• Registration Number: NCT01819740
• Lead Sponsor: Corporacion Parc Tauli

Brief Summary

The aim of our study is to determine if the levels of the "HEM" substance in seminal plasma are associated with the presence of prostate cancer in transrectal prostate biopsy.

Detailed Description

Not available

Study Timeline

• Status Verified: 2013-03
• Study First Submitted: 2013-03-25
• Study First Submitted QC: 2013-03-27
• Last Update Submitted: 2013-03-27
• Study First Posted: 2013-03-28
• Last Update Posted: 2013-03-28
• Study Start: 2013-04
• Primary Completion: 2013-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 28

Inclusion Criteria

• Clinical or laboratory suspected of prostate cancer

Exclusion Criteria

• Inability to ejaculate

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
patients with suspected prostate cancer	determine the levels of the "HEM" substance in seminal plasma	-

Primary Outcome Measures

Name	Time	Method
substance "HEM" concentration in seminal plasma (mEq/L measured by spectro-photometry	1 hour

Trial Locations

Locations (1)

Hospital Universitario Parc Taulí; 🇪🇸 Sabadell, Barcelona, Spain